甲磺酸伊马替尼片联合复方黄黛片治疗慢性髓性白血病慢性期12例临床疗效观察

Clinical Observation on 12 Cases of Imatinib Combined With Compound Huangdai Tablets in the Treatment of Chronic Myeloid Leukemia in Chronic Phase

目的观察慢性髓性白血病慢性期（CML-CP）应用伊马替尼、复方黄黛片的临床疗效及不良反应。方法对12例患者应用伊马替尼300-400 mg/d,复方黄黛片5-8片/次,3次/d,观察3、6、12个月时血液学、染色体、BCR-ABL基因变化,评价并统计患者临床疗效与不良反应。结果治疗3个月后缓解率100%;6个月缓解率83.3%;12个月后缓解率91.7%。患者发生白细胞和血小板减少的8例,单纯血小板减少的4例;输血小板1例,发生手部皮疹1例,胃肠道反应3例。结论伊马替尼联合复方黄黛片能提高CML-CP患者的临床缓解情况,减少不良反应发生率。

Objective To observe the clinical efficacy and adverse reactions of chronic myeloid leukemia in chronic phase（CML-CP） used imatinib and compound Huangdai tablets. Methods 12 patients with imatinib 300 to 400 mg/d,5 to 8 tablets each time for compound Huangdai tablets,3 times /d. Observation of 3,6,12 months of blood,chromosome,BCR-ABL gene changes,evaluation and statistics of patients with clinical efficacy and adverse reactions. Results After 3 months of treatment,the remission rate was 100%. 6 months later,the remission rate was 83.3%,12 months later,the remission rate was 91.7%. There were 8 cases of white blood cell decrease and thrombocytopenia,4 cases of simple thrombocytopenia,1 cases of platelet transfusion,1 cases of hand skin rash,3 cases of gastrointestinal reaction. Conclusion Imatinib combined with compound Huangdai tablets can improve the clinical remission of CML-CP patients,reduce the incidence of adverse reaction.